Lisata's LSTA201 trial in diabetic kidney disease fails to show consistent kidney function improvement

LISATA THERAPEUTICS, INC.

Preliminary unaudited cash, equivalents and marketable securities of ~$69.2M as of Dec 31, 2022.
Phase 1b trial of LSTA201 (CD34+ cell therapy) in 6 DKD patients tolerated but no consistent kidney function improvement.
Company will evaluate data and determine next steps; no further clinical study committed.
Corporate presentation attached as Exhibit 99.1 for investor conference use.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.